Clinical Trials Logo

Pompe Disease (Late-onset) clinical trials

View clinical trials related to Pompe Disease (Late-onset).

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06178432 Not yet recruiting - Clinical trials for Pompe Disease (Late-onset)

Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)

Start date: December 2023
Phase: Early Phase 1
Study type: Interventional

This is a single-center, single-arm, open-label, single-dose treatment clinical study to evaluate the safety, tolerability and efficacy of CRG003 injection in participants with late onset Pompe disease (LOPD), with a long-term follow-up period of 5 years. CRG003 (BBM-G102) injection is an adeno-associated virus (AAV) gene therapy product for treating Pompe disease to stably express active GAA enzyme in the liver on a long-term basis after the injection.